Pharma Industry News

Novartis’ Ilaris first drug approved for Still’s disease

Ilaris works by blocking the effects of IL-1 and suppressing inflammation in patients with this autoinflammatory disorderOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]